PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
April 3, 2026Biomedicine & PharmacotherapyOpen Access

Leukemic stem cells as drivers of therapeutic resistance in acute myeloid leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

SSSuellen L.R. SilvaGBGabriela A. da C. BarbosaJRJoão V.B. Rios

Discussion

Loading...

Member takes

Overview

Review summarizes mechanisms of therapeutic resistance in acute myeloid leukemia driven by leukemic stem cells, suggesting new treatment strategies.

Key Points

  • The aim is to understand how leukemic stem cells contribute to therapy resistance in acute myeloid leukemia.
  • Reviewed biological pathways sustaining leukemic stem cell-mediated resistance in AML.
  • Discussed intrinsic and extrinsic mechanisms affecting LSC survival.
  • Analyzed emerging therapies targeting leukemic stem cells.
  • Leukemic stem cells are crucial for sustaining therapy resistance and disease relapse in AML.
  • Intrinsic mechanisms include cellular quiescence and multidrug efflux activity.
  • LSCs show adaptive metabolic and epigenetic responses to therapies.
  • Bone marrow microenvironment interactions enhance LSC survival.
  • Targeting LSC vulnerabilities may improve treatment outcomes.

Cite This Study

Silva et al. (2026) studied this question.

synapsesocial.com/papers/69cf58cb5a333a8214609a4fhttps://doi.org/10.1016/j.biopha.2026.119295
View Full Paper
Ask AI
Bookmark
Share